1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Product-Specific or Class-Specific Biosimilar Guidances? US FDA Wants Feedback

 
• By Sarah Karlin-Smith

The FDA’s experience with product-specific guidances for generic drugs may impact biosimilar industry decision-making, but the program has improved in recent years.

monoclonal antibdoy
Biosimilar sponsors have 90 days to suggest the type of guidance that would be most helpful from the FDA. • Source: Shutterstock

The US Food and Drug Administration wants industry input on whether product-specific or class-specific guidance would be more useful for accelerating biosimilar development.

Key Takeaways

  • Biosimilars sponsors are asked to give the FDA feedback on whether product-specific or class-specific guidance would be most helpful for speeding development.

The agency also is seeking feedback on whether to focus on development of guidance documents for biologics with no approved...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

US Supreme Court Wants Solicitor General Input On Hikma Skinny Label Case

 
• By Dean Rudge

The US Supreme Court is seeking the administration's view following the Federal Circuit decided to reopen Amarin’s case against the ‘skinny-label’ generic Vascepa (icosapent ethyl).

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 
• By Eliza Slawther

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.